PCSK9 and familial hypercholesterolemia: This phase 2 trial included patients with “refractory hypercholesterolemia” defined by an LDL-cholesterol level of ≥70 mg/dl or higher in the presence of ASCVD or ≥100 mg/dl in the absence of atherosclerotic cardiovascular on background treatment with maximally tolerated statins with or without ezetimibe and the highest available dose of a PCSK9 inhibitor (73).